AQR Arbitrage’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

AQR Arbitrage’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-357,585	Closed	-$3.75M	–	689
2026 Q1	$3.75M	Sell	357,585 -13,626	-4%	-$142K	0.06%	274
2025 Q4	$3.85M	Hold	371,211	–	–	0.08%	235
2025 Q3	$3.81M	Sell	371,211 -5,103	-1%	-$52.4K	0.1%	209
2025 Q2	$3.84M	Sell	376,314 -4,000	-1%	-$40.4K	0.09%	183
2025 Q1	$3.81M	Buy	+380,314	New	+$3.8M	0.09%	179

Other funds holding DMAA

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

AQR Arbitrage's DMAA Position: Q2 2026 in Review

AQR Arbitrage sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 357,585 shares — an estimated $3.75M sold.

AQR Arbitrage first reported a position in DMAA in Q1 2025 and held it in 5 quarters. The position peaked at $3.85M in Q4 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

AQR Arbitrage reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
AQR Arbitrage sold 357,585 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $3.75M.
AQR Arbitrage first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 5 quarters.
AQR Arbitrage's Drugs Made In America Acquisition Corp position peaked at $3.85M in Q4 2025.
23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on AQR Arbitrage's 13F filing for Q2 2026, filed 14 Aug 2026.